| __timestamp | AbbVie Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4426000000 | 72049000 |
| Thursday, January 1, 2015 | 4500000000 | 110777000 |
| Friday, January 1, 2016 | 5833000000 | 156328000 |
| Sunday, January 1, 2017 | 7040000000 | 175820000 |
| Monday, January 1, 2018 | 7718000000 | 143944000 |
| Tuesday, January 1, 2019 | 7439000000 | 160152000 |
| Wednesday, January 1, 2020 | 15387000000 | 188519000 |
| Friday, January 1, 2021 | 17446000000 | 258234000 |
| Saturday, January 1, 2022 | 17414000000 | 311103000 |
| Sunday, January 1, 2023 | 20415000000 | 384447000 |
| Monday, January 1, 2024 | 16904000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for AbbVie Inc. and HUTCHMED (China) Limited from 2014 to 2023. Over this period, AbbVie Inc. has demonstrated a significant increase in cost efficiency, with its cost of revenue growing by approximately 360%, from $4.4 billion in 2014 to $20.4 billion in 2023. In contrast, HUTCHMED's cost of revenue increased by around 434%, from $72 million to $384 million. Despite the disparity in absolute numbers, both companies have shown a consistent upward trend, reflecting their expanding operations and market reach. This comparison highlights the dynamic nature of the pharmaceutical sector, where strategic cost management can lead to substantial growth and competitive advantage.
Cost of Revenue Trends: AbbVie Inc. vs Catalent, Inc.
Analyzing Cost of Revenue: AbbVie Inc. and ADMA Biologics, Inc.
Cost Insights: Breaking Down AbbVie Inc. and Evotec SE's Expenses
Cost of Revenue Trends: AbbVie Inc. vs Xencor, Inc.
Cost of Revenue Comparison: Incyte Corporation vs HUTCHMED (China) Limited
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs HUTCHMED (China) Limited
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and HUTCHMED (China) Limited
Cost of Revenue Comparison: Cytokinetics, Incorporated vs HUTCHMED (China) Limited
Analyzing Cost of Revenue: Amneal Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Cost of Revenue: Key Insights for CRISPR Therapeutics AG and HUTCHMED (China) Limited
Bausch Health Companies Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for HUTCHMED (China) Limited and Dyne Therapeutics, Inc.